Multiple Sclerosis and Depression
Depression is very common in people with multiple sclerosis (MS). In fact, symptoms of depression severe enough to require medical intervention affect up to…
Myelin Repair Foundation appointed Dr. Alfred Sandrock, Chief Medical Officer from Biogen Idec to our Clinical Advisory Board
We are very pleased to announce that this week the Myelin Repair Foundation appointed Dr. Alfred Sandrock, Chief Medical Officer…
Stuart Schlossman
BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
Proposed Trial Will Build on NurOwn™ Platform to Meet Unmet Needs of Patients with Neurodegenerative Disorders NEW YORK & PETACH…
Stuart Schlossman
Will StemCells Walk The Talk?
3/7/2012 5:12 AM ET (RTTNews) – Stem cells have set the scientific world agog because it has been proposed as…
Stuart Schlossman
Researcher in Regina to discuss new advances in MRI techniques
REGINA — Dr. Melanie Martin hopes her research on the brain will allow her to make tools doctors can use…
Stuart Schlossman
Dr. Terry Wahls’ information on her diet for Multiple Sclerosis
Previous postings Dr. Terry Wahls, claims her diet has cured her MS – Minding Your … Dec 15, 2011 Dr. Terry Wahls,…
Stuart Schlossman
MS News clips from the National MS Society
Lifescript.com which attracts 6.7 million visitors monthly has added an MS Health Center to its site which includes a summary of new MS therapies…
Stuart Schlossman
Okay we already know that smoking is bad for you. But with MS it is even worse
http://www.nationalmssociety.org/Research-2005Apr28-2.asp NMSS study on smoking and progression http://www.nationalmssociety.org/Sourcebook-Smoking.asp Info on smoking from the NMSS Sourcebook http://www.medscape.com/viewarticle/503872?src=mp Smoking may…
Stuart Schlossman
Social Security Expands Compassionate Allowances List
Posted by Doug LandauFebruary 14, 2012 From Stuart: Some of the wording baffles me in the article found below, like Malignant…
Stuart Schlossman
The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical trial on TDI 132 (aka: fingolimod/Gilenya(R)) as a potential treatment for ALS (Lou Gehrig’s disease)
Feb 14, 2012 CAMBRIDGE, Mass., Feb. 14, 2012 /PRNewswire-USNewswire/ — The ALS Therapy Development Institute (ALS TDI) will launch a Phase II clinical…
Stuart Schlossman
